[
  {
    "ts": null,
    "headline": "Here's How Much You'd Have If You Invested $1000 in Eli Lilly a Decade Ago",
    "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
    "url": "https://finnhub.io/api/news?id=d0cae16f7919c181ceeb07e729ac185ead86b5e3525f5a7aa009ac4d318687e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757366990,
      "headline": "Here's How Much You'd Have If You Invested $1000 in Eli Lilly a Decade Ago",
      "id": 136674199,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
      "url": "https://finnhub.io/api/news?id=d0cae16f7919c181ceeb07e729ac185ead86b5e3525f5a7aa009ac4d318687e3"
    }
  },
  {
    "ts": null,
    "headline": "Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang",
    "summary": "LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it has received a strategic investment from Goose Capital and former Tanox, Inc. CEO Dr. Nancy T. Chang, Goose founding member. At Tanox, Dr. Chang and her team invented and developed FDA-approved XOLAIR® (omalizumab) for severe asthma, TROGAR",
    "url": "https://finnhub.io/api/news?id=36e513605f67d3dce456b5728ac538012557c16a3f7834e1e8bd394ae5b8b526",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757365500,
      "headline": "Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang",
      "id": 136674200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it has received a strategic investment from Goose Capital and former Tanox, Inc. CEO Dr. Nancy T. Chang, Goose founding member. At Tanox, Dr. Chang and her team invented and developed FDA-approved XOLAIR® (omalizumab) for severe asthma, TROGAR",
      "url": "https://finnhub.io/api/news?id=36e513605f67d3dce456b5728ac538012557c16a3f7834e1e8bd394ae5b8b526"
    }
  },
  {
    "ts": null,
    "headline": "WHO adds GLP-1RAs to essential medicines list",
    "summary": "Old and new-generation diabetes and obesity drugs such as Wegovy, Zepbound, Saxenda and Trulicity have made the list.",
    "url": "https://finnhub.io/api/news?id=c198d4181e763537f87f86a9cff7be9467d903af57cb578074548b23631681b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757357953,
      "headline": "WHO adds GLP-1RAs to essential medicines list",
      "id": 136674201,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Old and new-generation diabetes and obesity drugs such as Wegovy, Zepbound, Saxenda and Trulicity have made the list.",
      "url": "https://finnhub.io/api/news?id=c198d4181e763537f87f86a9cff7be9467d903af57cb578074548b23631681b1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Announces Promising Results For Jaypirca In CLL Phase 3 Trial",
    "summary": "Eli Lilly (LLY) recently announced positive results from its Phase 3 BRUIN CLL-313 trial, revealing significant progression-free survival improvements for its drug Jaypirca in treatment-naive CLL/SLL patients. This announcement likely played a key role in the company’s 16% share price rise over the past month. The FDA's Breakthrough Therapy designation for the company's olomorasib, targeting NSCLC in combination with KEYTRUDA, supports their innovative momentum. These developments, occurring...",
    "url": "https://finnhub.io/api/news?id=2ceefd83458b2b8c556347278560c003767affd10ca8b4b05b8eded6cad06949",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757355958,
      "headline": "Eli Lilly (LLY) Announces Promising Results For Jaypirca In CLL Phase 3 Trial",
      "id": 136674202,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) recently announced positive results from its Phase 3 BRUIN CLL-313 trial, revealing significant progression-free survival improvements for its drug Jaypirca in treatment-naive CLL/SLL patients. This announcement likely played a key role in the company’s 16% share price rise over the past month. The FDA's Breakthrough Therapy designation for the company's olomorasib, targeting NSCLC in combination with KEYTRUDA, supports their innovative momentum. These developments, occurring...",
      "url": "https://finnhub.io/api/news?id=2ceefd83458b2b8c556347278560c003767affd10ca8b4b05b8eded6cad06949"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Recommends Eli Lilly Over Viking Therapeutics",
    "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer shared insights on. When a caller asked about the company during the lightning round, Cramer commented: “No, no, no. We have Eli Lilly. Why do we have to settle? Let’s, don’t, don’t go for the raggedy rest. Let’s go for the best.” Viking Therapeutics, […]",
    "url": "https://finnhub.io/api/news?id=8fb45392cae80e104db1b9ea1027839a7ff7b331ffcc6fec46063cc816825499",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757350739,
      "headline": "Jim Cramer Recommends Eli Lilly Over Viking Therapeutics",
      "id": 136674203,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer shared insights on. When a caller asked about the company during the lightning round, Cramer commented: “No, no, no. We have Eli Lilly. Why do we have to settle? Let’s, don’t, don’t go for the raggedy rest. Let’s go for the best.” Viking Therapeutics, […]",
      "url": "https://finnhub.io/api/news?id=8fb45392cae80e104db1b9ea1027839a7ff7b331ffcc6fec46063cc816825499"
    }
  },
  {
    "ts": null,
    "headline": "NKTR Shares Surge 38.2% in a Week: Here's What You Should Know",
    "summary": "Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.",
    "url": "https://finnhub.io/api/news?id=f18eccb09b5f3da68a641d02a4d61090c3d8abc1213d72e0cc21b2f1d9476faa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757348820,
      "headline": "NKTR Shares Surge 38.2% in a Week: Here's What You Should Know",
      "id": 136674204,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.",
      "url": "https://finnhub.io/api/news?id=f18eccb09b5f3da68a641d02a4d61090c3d8abc1213d72e0cc21b2f1d9476faa"
    }
  },
  {
    "ts": null,
    "headline": "How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story",
    "summary": "On August 26, 2025, Chugai Pharmaceutical reported that Eli Lilly announced positive topline Phase 3 results for orforglipron, an investigational oral GLP-1 receptor agonist for adults with obesity or overweight and type 2 diabetes, meeting all primary and key secondary endpoints. This marks a potential advancement in oral obesity and diabetes therapies, with the results reflecting the impact of Chugai's partnership with Eli Lilly on innovation in high-demand therapeutic areas. We’ll explore...",
    "url": "https://finnhub.io/api/news?id=43c4050000530d2ad2e936c52fccccf15f0c48c93e88a6db0cd5c41c57dca7d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757344551,
      "headline": "How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story",
      "id": 136674205,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On August 26, 2025, Chugai Pharmaceutical reported that Eli Lilly announced positive topline Phase 3 results for orforglipron, an investigational oral GLP-1 receptor agonist for adults with obesity or overweight and type 2 diabetes, meeting all primary and key secondary endpoints. This marks a potential advancement in oral obesity and diabetes therapies, with the results reflecting the impact of Chugai's partnership with Eli Lilly on innovation in high-demand therapeutic areas. We’ll explore...",
      "url": "https://finnhub.io/api/news?id=43c4050000530d2ad2e936c52fccccf15f0c48c93e88a6db0cd5c41c57dca7d3"
    }
  },
  {
    "ts": null,
    "headline": "Investing in Oncology: 3 Cancer Stocks With Promising Pipelines",
    "summary": "Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.",
    "url": "https://finnhub.io/api/news?id=02c685ac8dfbbeca17a408004c250987e0afabc680a0cc7b012a40defe6de411",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757342520,
      "headline": "Investing in Oncology: 3 Cancer Stocks With Promising Pipelines",
      "id": 136674206,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.",
      "url": "https://finnhub.io/api/news?id=02c685ac8dfbbeca17a408004c250987e0afabc680a0cc7b012a40defe6de411"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly And Company (LLY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)",
    "summary": "Get insights from Eli Lilly's 2025 strategy at Morgan Stanleyâs Healthcare Conference",
    "url": "https://finnhub.io/api/news?id=7898fa68e6a142c721a51b00e9bead7788eee57ffba0ed078cc0db2c19ada188",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757334871,
      "headline": "Eli Lilly And Company (LLY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)",
      "id": 136670779,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Get insights from Eli Lilly's 2025 strategy at Morgan Stanleyâs Healthcare Conference",
      "url": "https://finnhub.io/api/news?id=7898fa68e6a142c721a51b00e9bead7788eee57ffba0ed078cc0db2c19ada188"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, versus chemoimmunotherapy (bendamustine plus rituximab), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions. The study met its primary endpoint, demonstrating a highly statistically significant and clinically",
    "url": "https://finnhub.io/api/news?id=a434ef228429abf64291f4cc22ab061e500ddc6b931d66ee3b45ead51cc1dd68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757331900,
      "headline": "Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL",
      "id": 136669085,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, versus chemoimmunotherapy (bendamustine plus rituximab), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions. The study met its primary endpoint, demonstrating a highly statistically significant and clinically",
      "url": "https://finnhub.io/api/news?id=a434ef228429abf64291f4cc22ab061e500ddc6b931d66ee3b45ead51cc1dd68"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Tesla Market Share Struggles",
    "summary": "Teslaâs share of U.S. EVE market drops below 40%. UnitedHealth reaffirms outlook. Goldman sees global music revenues doubling by 2035.",
    "url": "https://finnhub.io/api/news?id=9c7c329594b51e53ab74fc5bd34d650ce4884d5b9a184c07c6f97e665af4b42a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757330736,
      "headline": "Wall Street Lunch: Tesla Market Share Struggles",
      "id": 136670519,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2168818243/image_2168818243.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Teslaâs share of U.S. EVE market drops below 40%. UnitedHealth reaffirms outlook. Goldman sees global music revenues doubling by 2035.",
      "url": "https://finnhub.io/api/news?id=9c7c329594b51e53ab74fc5bd34d650ce4884d5b9a184c07c6f97e665af4b42a"
    }
  },
  {
    "ts": null,
    "headline": "Weight loss has become the hottest new Chinese consumer craze",
    "summary": "Weight loss has become the hottest new Chinese consumer craze",
    "url": "https://finnhub.io/api/news?id=9973ebc213c10e8e925e74b0bb6d6f8c6473b28f504515a085b38d8d9745c1b3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757328960,
      "headline": "Weight loss has become the hottest new Chinese consumer craze",
      "id": 136712938,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Weight loss has become the hottest new Chinese consumer craze",
      "url": "https://finnhub.io/api/news?id=9973ebc213c10e8e925e74b0bb6d6f8c6473b28f504515a085b38d8d9745c1b3"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: A Pharma Leader With Growth Potential And Portfolio-Defensive Appeal",
    "summary": "Discover why Novo Nordisk is a top buy with strong GLP-1 drug growth, robust fundamentals, and defensive value.",
    "url": "https://finnhub.io/api/news?id=0177e45e29812db3b1713d332ac45d3d61e766bf6a98ddbf329c4f0df4ce4a1a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757325480,
      "headline": "Novo Nordisk: A Pharma Leader With Growth Potential And Portfolio-Defensive Appeal",
      "id": 136669055,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305291/image_2158305291.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why Novo Nordisk is a top buy with strong GLP-1 drug growth, robust fundamentals, and defensive value.",
      "url": "https://finnhub.io/api/news?id=0177e45e29812db3b1713d332ac45d3d61e766bf6a98ddbf329c4f0df4ce4a1a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs",
    "summary": "Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why LLY stock is rated a 'Buy' now.",
    "url": "https://finnhub.io/api/news?id=7ff15342da5ffe044e2eb13a1d532421323b86ad8fcc88d283203eb5cf3587c4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757316643,
      "headline": "Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs",
      "id": 136668317,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196154167/image_2196154167.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why LLY stock is rated a 'Buy' now.",
      "url": "https://finnhub.io/api/news?id=7ff15342da5ffe044e2eb13a1d532421323b86ad8fcc88d283203eb5cf3587c4"
    }
  },
  {
    "ts": null,
    "headline": "Unpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals Stocks",
    "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Eli Lilly (NYSE:LLY) and the best and worst performers in the branded pharmaceuticals industry.",
    "url": "https://finnhub.io/api/news?id=299f32960adbb59a1b1c8ef80f9a43b3b650aaa3dbce54cbfe7eb864b856fee2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757305953,
      "headline": "Unpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals Stocks",
      "id": 136669086,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Eli Lilly (NYSE:LLY) and the best and worst performers in the branded pharmaceuticals industry.",
      "url": "https://finnhub.io/api/news?id=299f32960adbb59a1b1c8ef80f9a43b3b650aaa3dbce54cbfe7eb864b856fee2"
    }
  }
]